anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Potassium Phosphates Injection, USP 3 mM P/mL is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum potassium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of millimoles (mM) of phosphorus.

In adult patients receiving TPN (total parenteral nutrition), a dose of 12 to 15 mM phosphorus is recommended for each 500 mL of 50% Dextrose Injection, USP administered. The amount of potassium which accompanies the addition of phosphorus as potassium phosphate also should be kept in mind and if necessary, serum potassium levels and/or electrocardiographic changes should be monitored.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.
Disclose flavivirus recombinant and application thereof at this, the virus recombinant that is used to cell inner expression allogenic polypeptide is provided. This virus recombinant is derived from japanese encephalitis virus (JEV). This virus recombinant encoding fusion protein, does it comprise external source (, non-JEV) polypeptide and JEV non-structural protein 1 (JEV? or its fragment NS1). Does is above-mentioned allogenic polypeptide inserted in JEV? the c-terminus of NS1, and the production of this recombination fusion protein can not affect virus replication. In the time utilizing this virus recombinant infection cell, can produce the JEV particle that comprises limited proliferative virion (LMV). Each LMV comprises above-mentioned JEV replicon. JEV particle can be used to bring out in host the immune response to this allogenic polypeptide, and thereby makes this host possess the protection immunity of this allogenic polypeptide of antagonism.
<P>PROBLEM TO BE SOLVED: To provide a high safety composition for diet derived from a raw coffee bean by which superior diet effect can be obtained, and which is useful for prevention and treatment of life cycle-related diseases such as diabetes.  <P>SOLUTION: The composition for diet of the invention is characterised by containing a polar solvent extract of a degreased coffee bean as an effective component. The polar solvent extract is preferably a hydrous ethanol extract, more preferably a hydrous ethanol extract with a 40-90% (wt/wt) ethanol. The degreased raw coffee bean is preferably a raw coffee bean of which the oil component is extracted and separated with N-hexane. The composition for diet of the invention is preferably combindedly used together with any one kind or more kinds of Salacia extract, Oensothera tetraptera extract, Sesamin and Galcinia. The composition for diet of the invention can be used as a raw material for food and drink, medicine, or dermal outer-use agent.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Systems, methods, and computer program product embodiments are disclosed for performing electrophysiology (EP) signal processing. An embodiment includes an electrocardiogram (ECG) circuit board configured to process an ECG signal. The embodiment further includes a plurality of intracardiac (IC) circuit boards, each configured to process a corresponding IC signal. The embodiment further includes a communications interface communicatively coupled to a remote device, and a processor, coupled to the ECG circuit board, the plurality of IC circuit boards, and the communications interface. The processor is configured to receive, via the communications interface, feedback from the remote device. The processor is further configured to control, via the communication interface, the remote device based on the ECG signal, the IC signals, or the feedback from the remote device.
Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy. Advancing PD is associated with disabling axial motor complications, such as freezing of gait (FoG), with decreased or even refractory dopamine responsiveness in over 50% of patients. The management of dopamine resistant gait problems represents the most important unmet need in PD. At present, there is no biomarker of FoG in patients with PD as there is a lack of mechanistic understanding of dopamine nonresponsiveness of FoG. The investigators have previously identified cholinergic denervation as a prominent factor related to both falls and gait slowing in PD. The investigators recently identified that cortical -amyloid deposition not only associates with cognitive decline but also with postural instability and gait difficulties in PD. In this proposal, the investigators present preliminary data suggesting that FoG is associated with either cholinopathy, amyloidopathy or both in PD. The investigators propose to test the novel hypothesis that comorbid amyloidopathy may be a possible mechanistic factor underlying the poor response of FoG to dopaminergic therapy in advancing PD. In contrast, isolated cholinopathy would be expected to be associated with preserved dopamine responsiveness of FoG. For this purpose, the investigators propose to perform detailed motor, including FoG, testing in PD patients "on" and "off" their dopaminergic medications and relate this to dopaminergic 11C-dihydrotetrabenazine (DTBZ), vesicular acetylcholine transporter 18F-fluoroethoxybenzovesamicol (FEOBV) and -amyloid 11C-labeled Pittsburgh Compound-B (PIB) brain PET imaging in PD subjects with and without FoG. Furthermore, based on recent clinical observations that serotoninergic drugs, like the popular anti-depressant selective serotonin reuptake inhibitor (SSRI) drugs, are associated with significantly lower build- up of -amyloid plaques in the elderly population, and based on the investigators' subsequent observation of an intriguing inverse relationship between -amyloid plaque deposition and striatal serotoninergic terminal in PD, the investigators propose to perform an exploratory sub-study to test a new hypothesis that PD subjects with FoG will exhibit not only higher striatal -amyloid but also lower striatal serotoninergic innervation (as determined by 11C-DASB serotonin PET imaging) compared to PD subjects without FoG. If confirmed, positive findings in this study would allow the identification of different PD subgroups ('personalized medicine'), such as presence amyloidopathy or cholinopathy, to select patients for targeted pharmacotherapies to potentially prevent the development of FoG (anti-amyloid, such as serotoninergic drugs) or manage its clinical manifestation (cholinergic augmentation therapy) in order to preserve and maintain a good quality of life in individuals with PD.
Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 cycles.
PROBLEM TO BE SOLVED: To provide a method capable of efficiently producing a large amount of an embrocation of ointment, extremely high in SOD concentration, having successively admittable effect. SOLUTION: Rooibos tea in an amount of 5-20g is added to 100ml of a buffer solution of (0.1M) sodium hydrogen phosphate at 0-10 deg.C at pH7.0-7.8, stirred and filtered by a coarse filter having 50-70 microns not eluting components. The filtrate is filtered by a fine filter having 25-40 microns not eluting the components. The filtrate is wrapped in a permeable membrane, the wraps are thrown in a solution to elute sodium hydrogenphosphate more readily than the wraps of the permeable membrane. The residual solution is taken out from the wraps of the permeable membrane and the takeout solution is highly concentrated by a membrane separation method. The solution is mixed with an absorption ointment having a volume of ten times as much as the solution. The whole operations are carried out while maintaining the solution at 0-10 deg.C.  SOD is called superoxide dismutase, becomes a reaction catalyst for 2H+2O2 <-> →H2 O2 +O2 , decomposes excessive active oxygen in vivo and effectively prevents the occurrence of organism tissue disorder caused by excessive active oxygen.
Undertreatment with ALKINDI SPRINKLE or sudden discontinuation of therapy with ALKINDI SPRINKLE may lead to adrenocortical insufficiency, adrenal crisis, and death. Adrenal crisis may also be induced by stress events such as infections or surgery when patients require higher doses of corticosteroids. Symptoms of adrenocortical insufficiency include poor feeding, fatigue, low muscle tone, joint pain, nausea, vomiting, hypoglycemia, low blood pressure and electrolyte disturbances.

  
Increase the dosage of ALKINDI SPRINKLE during periods of stress (infections, surgery). Switch patients who are vomiting, severely ill or unable to take oral medications to parenteral corticosteroid formulations without delay. Once the patient recovers, gradually reduce the steroid dosage used during the acute event. 

  
When switching patients to ALKINDI SPRINKLE from another oral hydrocortisone formulation, consider the potential for dosing inaccuracy if the other oral hydrocortisone formulation has been manipulated (e.g., split or crushed tablets, compounded formulations). Manipulation of oral hydrocortisone formulations may result in a relative difference in hydrocortisone exposure when using the same dosage to initiate ALKINDI SPRINKLE treatment. Closely monitor patients after switching to ALKINDI SPRINKLE to ensure ALKINDI SPRINKLE is providing the same level of hydrocortisone exposure as the previously used oral hydrocortisone formulation. If symptoms of adrenal insufficiency occur, increase the total daily dosage of ALKINDI SPRINKLE.
BACKGROUND: Heavy menstrual bleeding (HMB) affects up to 37% of adolescents. Without recognition, HMB can lead to other medical conditions resulting in diminished health-related quality of life. WeThrive, a new mobile health (mHealth) app, implements the pictorial bleeding assessment chart to identify HMB, and the adolescent Menstrual Bleeding Questionnaire to measure the effects of HMB on adolescents' health-related quality of life. If HMB is identified, WeThrive will connect users to local clinics for further assessment of their menstrual bleeding with a health care provider.
OBJECTIVE: This study aimed to describe adolescents' experiences using WeThrive app.
METHODS: This qualitative study was approved by the local Research Ethics Board in Halifax, Nova Scotia, and informed consent was provided by all participants. Individual semistructured interviews were held via videoconference with adolescents younger than 18 years, who had at least 1 menstrual period and had used WeThrive at least once. Interview transcripts were thematically analyzed by 2 investigators (MP and NMN) independently, and the κ statistic was calculated to determine the strength of correlation in themes.
RESULTS: Five adolescents (mean age 15.5, range 13-18 years), participated in the interviews. All participants stated that WeThrive helps them better understand their menstrual periods by predicting period onset, recognizing menstrual symptoms, and identifying HMB. Four themes were identified: (1) the importance of visual features and usability, (2) newly obtained knowledge using WeThrive, (3) feature use depends on menstrual health, and (4) trustworthiness. There was substantial agreement on the identified themes (κ=0.73).
CONCLUSIONS: WeThrive is visually appealing, and trustworthy, and helps users better understand their menstrual periods, including identifying HMB. By identifying HMB early, WeThrive has the potential to improve the recognition of bleeding disorders and iron deficiency in adolescents. WeThrive is a useful tool to help adolescents better understand their menstrual periods.
OBJECTIVES: Cement penetration (CP) plays a key role in implant stability for cemented total knee arthroplasty (TKA), and the radiolucent line (RLL) >2 ​mm is a preliminary sign for loosening of components. However, the direct relationship between CP and the frequency of RLL >2 ​mm is unclear, and the best cut-off value for CP to prevent RLL >2 ​mm also remains unclear. This study aimed to investigate this relationship between CP and RLL and to determine the clinical cut-off value for tibial CP in patients 2 years after TKA.
METHODS: This retrospective study investigated 157 knees from 123 patients with osteoarthritis who underwent cemented TKA. The CP and RLL immediately after TKA and the RLL 2 years after TKA were measured for the medial, lateral, anterior, and posterior tibial baseplate zones. Receiver operating characteristic (ROC) curves were constructed to determine the best cut-off values for CP.
RESULTS: RLL >2 ​mm was not observed just after TKA. An RLL >2 ​mm was observed in any tibial baseplate zone in 22 knees from 20 patients (RLL+ group) and was not observed in the remaining (RLL- group) 2 years after TKA. The mean CP for all zones was significantly higher in the RLL- group (2.5 ​± ​1.1 ​mm) than in the RLL+ group (1.7 ​± ​0.6 ​mm; P ​< ​0.001). An RLL >2 ​mm was seen in 21 knees in the medial zone, 9 knees in the lateral zone, 8 knees in the anterior zone, and 3 knees in the posterior zone. CP values with RLL >2 ​mm were significantly lower than those without the RLL at the medial, anterior, and posterior tibial baseplate zones. The best cut-off values from the ROC curve of CP in each zone were between 1.1 ​mm and 2.1 ​mm.
CONCLUSIONS: The depth of the CP directly affects the incidence of an RLL >2 ​mm. The best cut-off value for tibial CP to prevent an RLL >2 ​mm is 2.1 ​mm.
Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Salt-sensitive hypertension is often more prone to induce damage to target organs such as the heart and kidneys. Abundant recent studies have demonstrated a close association between ferroptosis and cardiovascular diseases. Therefore, we hypothesize that ferroptosis may be closely associated with organ damage in salt-sensitive hypertension. This study aimed to investigate whether ferroptosis is involved in the occurrence and development of myocardial fibrosis and renal fibrosis in salt-sensitive hypertensive rats.
METHODS: Ten 7-week-old male Dahl salt-sensitive (Dahl-SS) rats were adaptively fed for 1 week, then randomly divided into two groups and fed either a normal diet (0.3% NaCl, normal diet group) or a high-salt diet (8% NaCl, high-salt diet group) for 8 weeks. Blood pressure of the rats was observed, and analysis of the hearts and kidneys of Dahl-SS rats was conducted via hematoxylin-eosin (HE) staining, Masson staining, Prussian blue staining, transmission electron microscopy, tissue iron content detection, malondialdehyde content detection, immunofluorescence, and Western blot.
RESULTS: Compared to the normal diet group, rats in the high-salt diet group had increases in systolic blood pressure and diastolic blood pressure (P < 0.05); collagen fiber accumulation was observed in the heart and kidney tissues (P < 0.01), accompanied by alterations in mitochondrial ultrastructure, reduced mitochondrial volume, and increased density of the mitochondrial double membrane. Additionally, there were significant increases in both iron content and malondialdehyde levels (P < 0.05). Immunofluorescence and Western blot results both indicated significant downregulation (P < 0.05) of xCT and GPX4 proteins associated with ferroptosis in the high-salt diet group.
CONCLUSIONS: Ferroptosis is involved in the damage and fibrosis of the heart and kidney tissues in salt-sensitive hypertensive rats.
An improved endoscopic device which is introduced into the intestinal tract of a living organism and which operates autonomously therein, adapted to obtain and store or transmit one or more types of data such as visual image data, laser autofluorescensce data, or ultrasonic waveform data. In another aspect of the invention, an improved endoscopic device useful for implanting the aforementioned endoscopic smart probe is disclosed. In another aspect of the invention, apparatus for delivering agents including nanostructures, radionuclides, medication, and ligands is disclosed. In another aspect of the invention, apparatus for obtaining a biopsy of intestinal tissue is disclosed. In another aspect of the invention, apparatus for detecting the presence of one or more molecular species within the intestine is disclosed. Methods for inspecting and/or treating the interior regions of the intestinal tract using the aforementioned apparatus are also disclosed.
PROBLEM TO BE SOLVED: To prepare an ultraviolet absorbing pigment for cosmetics, stable, having high dispersibility, having ultraviolet absorbing effect, and useful for foundation or the like sparingly affecting the skin and having a good feel by making pigment powder for cosmetics include and be covered with an organic ultraviolet absorbing compound through the medium of an organic polymer. SOLUTION: This ultraviolet absorbing pigment for cosmetics is prepared by making (A) pigment powder for cosmetics [pref. tabular inorganic pigment powder (e.g. sericite or the like) or globular pigment powder (e.g. globular silica or the like)] include and be covered with (C) (pref. <=20 wt.%) organic ultraviolet absorbing compound (e.g. 2-ethylhexyl p-methoxycinnamate or the like) through the medium of (B) (pref. <30 wt/%) organic polymer [e.g. poly(methyl methacrylate) or the like]. The pigment is e.g. prepared by dissolving the ingredient B in a solvent such as dichloromethane and then by dissolving the ingredient C in the solution, followed by dispersing the ingredient A in the resultant solution and then by evaporating the solvent.
In recent years, the scientific community has been paying increasing attention to lesbian, gay, bisexual, transgender, queer, intersexual, asexual population, with a special focus on transgender and gender-diverse individuals. Globally, the percentage of adults who identify themselves as transgender varies between 0.3% and 0.5%, while approximately 0.5% to 4.5% of adults are estimated to identify as gender-diverse. Despite the growing visibility of transgender and gender-diverse community and the efforts towards their depathologization, healthcare still needs to address two fundamental issues: the inadequate preparation of healthcare staff regarding gender incongruence which results in mistreatment and discrimination and the lack of uniform and large-scale prospective data. Scientific evidence regarding the risk of developing breast cancer (BC) in these patients and the related benefits of BC screening are still limited and insufficient. The Associazione Italiana di Oncologia Medica (AIOM), reported that the risk of developing BC tends to increase in transgender women compared to cisgender men (standardized incidence ratio \[SIR\], 46.7; 95% CI, 27.2-75.4), although it does not reach the level of risk in cisgender women (SIR, 0.3; 95% CI, 0.2-0.4). Conversely, in transgender men, the risk of BC decreases when compared to cisgender women (SIR, 0.2; 95% CI, 0.1-0.5), but it still remains higher than the risk present in cisgender men (58.9; 95% CI, 18.7-142.2).As for the screening programs, there is a lower adherence among the transgender and non-conforming-gender population compared to the cisgender population, due to socio-economic barriers and a lack of clear recommendations supported by scientific evidence.The National Comprehensive Cancer Network (NCCN)and AIOM guidelines currently do not include specific recommendations for transgender individuals due to the aforementioned lack of scientific evidence.

The American College of Radiology (ACR) regulates screening protocols for the transgender population based on factors such as age, hormone therapy exposure, surgical history, and risk categories.
A young adult male developed a left-sided pinna haematoma after a rugby injury. The haematoma reaccumulated after multiple attempts at drainage under local anaesthetic in emergency rooms and required incision and drainage in the theatre under general anaesthetic. Intraoperatively, multiple venous bleeding points were identified and these were controlled with bipolar diathermy. The wound was closed and dressed with bolster and crepe bandage. On day 7 postoperatively, the sutures and dressings were removed and the haematoma had not recurred. He returned to playing rugby on day 21 postoperatively and sustained another blunt impact to his left ear. He noticed new swelling over the posterior aspect of the same ear. This was drained via needle aspiration and there was no further reaccumulation of the pinna haematoma.
Participants will listen to the following auditory cues \~30 seconds apart Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job.
BACKGROUND: Dietary modification is the mainstay of treatment for postoperative chylothorax in children. However, optimal fat-modified diet (FMD) duration to prevent recurrence is unknown. Our aim was to determine the association between FMD duration and chylothorax recurrence.
METHODS: Retrospective cohort study conducted across 6 pediatric cardiac intensive care units within the United States. Patients aged <18 years who developed chylothorax within 30 days after cardiac surgery between January 2020 and April 2022 were included. Patients with a Fontan palliation, who died, or were lost to follow-up or within 30 days of resuming a regular diet were excluded. FMD duration was defined as the first day of a FMD when chest tube output was <10 mL/kg/d without increasing until the resumption of a regular diet. Patients were classified into 3 groups (<3 weeks, 3-5 weeks, >5 weeks) based on FMD duration.
RESULTS: A total of 105 patients were included: <3 weeks (n = 61) 3-5 weeks (n = 18), and >5 weeks (n = 26). Demographic, surgical, and hospitalization characteristics were not different across groups. In the >5 weeks group, chest tube duration was longer compared with the <3 weeks and 3-5 weeks groups (median, 17.5 days [interquartile range, 9-31] vs 10 and 10.5 days; P = .04). There was no recurrence of chylothorax within 30 days once chylothorax was resolving regardless of FMD duration.
CONCLUSIONS: FMD duration was not associated with recurrence of chylothorax, suggesting that FMD duration can safely be shortened to at least <3 weeks from time of resolving chylothorax.
PURPOSE: To obtain a microcapsule having a given size, consisting of acetylsalicylic acid(ASA) coated with a coating composition, and capable of controlling ASA release over the whole length of the digestive tract. CONSTITUTION: This microcapsule consists of an ASA particle 10-100 μm in size coated with a coating composition of a mixture of a cellulose-based film- forming polymer derivative, anti-tack agent, plasticizer, lubricant and vinyl-based film-forming polymer derivative. In the case of a single oral administration of the microcapsules at 75-320 mg, ASA absorption is induced over 24 h or longer. ASA absorption levels based on the portion to be absorbed are as follows: <=10 wt.% at 0.4 h after orally administered, <=50 wt.% at 3.9 h after orally administered, and <=90 wt.% at 23 h after orally administered. The microcapsules, for inhibiting thromboxane, can be used for preparing a selective aspirin galenical preparation, esp. being applicable, as a platelet aggregation inhibitor, against cardiovascular diseases.